Jump to content

Sepsis

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by SolomonHume (talk | contribs) at 11:48, 1 November 2012. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

For the genus of flies of this name, see Sepsis (genus).
Sepsis
SpecialtyInfectious diseases Edit this on Wikidata

Sepsis (/ˈsɛps[invalid input: 'ɨ']s/; from the Greek σῆψις: the state of putrefaction and decay) is a potentially deadly medical condition characterized by a whole-body inflammatory state (called a systemic inflammatory response syndrome or SIRS) that is triggered by an infection.[1][2] The body may develop this inflammatory response by the immune system to microbes in the blood, urine, lungs, skin, or other tissues. A popular term for sepsis is blood poisoning. Severe sepsis is the systemic inflammatory response, infection and the presence of organ dysfunction.

Septicemia (also septicaemia or septicæmia [ˌsɛp.tə.ˈsi.miə])[3] is a related medical term referring to the presence of pathogenic organisms in the bloodstream, leading to sepsis.[4] The term has not been sharply defined. It has been inconsistently used in the past by medical professionals, for example as a synonym of bacteremia, causing some confusion.[2]

Severe sepsis is usually treated in the intensive care unit with intravenous fluids and antibiotics. If fluid replacement isn't sufficient to maintain blood pressure, specific vasopressor medications can be used. Mechanical ventilation and dialysis may be needed to support the function of the lungs and kidneys, respectively. To guide therapy, a central venous catheter and an arterial catheter may be placed; measurement of other hemodynamic variables (such as cardiac output, mixed venous oxygen saturation, or stroke volume variation) may also be used. Sepsis patients require preventive measures for deep vein thrombosis, stress ulcers and pressure ulcers, unless other conditions prevent this. Some patients might benefit from tight control of blood sugar levels with insulin (targeting stress hyperglycemia).[5] The use of corticosteroids (low dose or otherwise) is controversial.[6] Activated drotrecogin alfa (recombinant activated protein C), originally marketed for severe sepsis, has not been found to be helpful,[7] and has recently been withdrawn from sale.[8]

Signs and symptoms

In addition to symptoms related to the provoking infection, sepsis is characterized by presence of acute inflammation present throughout the entire body, and is, therefore, frequently associated with fever and elevated white blood cell count (leukocytosis) or low white blood cell count (leukopenia) and lower-than-average temperature, and vomiting [citation needed]. The modern concept of sepsis is that the host's immune response to the infection causes most of the symptoms of sepsis, resulting in hemodynamic consequences and damage to organs. This host response has been termed systemic inflammatory response syndrome (SIRS) and is characterized by an elevated heart rate (above 90 beats per minute), high respiratory rate (above 20 breaths per minute or a partial pressure of carbon dioxide in the blood of less than 32), abnormal white blood cell count (above 12,000, lower than 4,000, or greater than 10% band forms) and elevated or lowered body temperature, i.e. under 36 °C (96.8 °F) or over 38 °C (100.4 °F). Sepsis is differentiated from SIRS by the presence of a known or suspected pathogen. For example, SIRS and a positive blood culture for a pathogen indicate the presence of sepsis. However, in many cases of sepsis no specific pathogen is identified.

This immunological response causes widespread activation of acute-phase proteins, affecting the complement system and the coagulation pathways, which then cause damage to the vasculature as well as to the organs. Various neuroendocrine counter-regulatory systems are then activated as well, often compounding the problem. Even with immediate and aggressive treatment, this may progress to multiple organ dysfunction syndrome and eventually death.

Diagnosis

Systemic inflammatory response syndrome[9]
Finding Value
Temperature <36 °C (96.8 °F) or >38 °C (100.4 °F)
Heart rate >90/min
Respiratory rate >20/min or PaCO2<32 mmHg (4.3 kPa)
WBC <4x109/L (<4000/mm3), >12x109/L (>12,000/mm3), or ≥10% bands

According to the American College of Chest Physicians and the Society of Critical Care Medicine,[2] there are different levels of sepsis:

Examples of end-organ dysfunction include the following:[10]

More specific definitions of end-organ dysfunction exist for SIRS in pediatrics.[11]

Consensus definitions, however, continue to evolve, with the latest expanding the list of signs and symptoms of sepsis to reflect clinical bedside experience.[1]

Neonatal sepsis

Main article: Neonatal sepsis

In common clinical usage, sepsis specifically refers to the presence of a bacterial blood stream infection (BSI), such as meningitis, pneumonia, pyelonephritis, or gastroenteritis. in the setting of fever. Criteria with regards to hemodynamic compromise or respiratory failure are not useful clinically because these symptoms often do not arise in neonates until death is imminent and unpreventable.

Pathophysiology

Systemic inflammatory response syndrome or SIRS is evidence of the body's ongoing inflammatory response. When SIRS is suspected or known to be caused by an infection, this is sepsis. Severe sepsis occurs when sepsis leads to organ dysfunction, such as pulmonary dysfunction, coagulation or other blood abnormalities, decreased urine production, or altered mental status. If the organ dysfunction of severe sepsis is associated with low blood pressure (hypotension), or insufficient blood flow (hypoperfusion) to one or more organs (causing, for example, lactic acidosis), this is septic shock.

Sepsis can lead to multiple organ dysfunction syndrome (MODS) (formerly known as multiple organ failure), and death. Organ dysfunction results from local changes in blood flow, from sepsis-induced hypotension (< 90 mmHg or a reduction of ≥ 40 mmHg from baseline) and from diffuse intravascular coagulation, among other things.

Sepsis can be defined as the body's response to an infection. An infection is caused by microorganisms or bacteria invading the body and can be limited to a particular body region or can be widespread in the bloodstream.

Bacteremia is the presence of viable bacteria in the bloodstream. Likewise, the terms viremia and fungemia simply refer to viruses and fungi in the bloodstream. These terms say nothing about the consequences this has on the body. For example, bacteria can be introduced into the bloodstream during toothbrushing.[12] This form of bacteremia almost never causes problems in normal individuals. However, bacteremia associated with certain dental procedures can cause bacterial infection of the heart valves (known as endocarditis) in high-risk patients.[13] Conversely, a systemic inflammatory response syndrome can occur in patients without the presence of infection, for example in those with burns, polytrauma, or the initial state in pancreatitis and chemical pneumonitis.[2]

Management

The therapy of sepsis rests on antibiotics, surgical drainage of infected fluid collections, fluid replacement and appropriate support for organ dysfunction. This may include hemodialysis in kidney failure, mechanical ventilation in pulmonary dysfunction, transfusion of blood products, and drug and fluid therapy for circulatory failure. Ensuring adequate nutrition—preferably by enteral feeding, but if necessary by parenteral nutrition—is important during prolonged illness.

A problem in the adequate management of septic patients has been the delay in administering therapy after sepsis has been recognized. Published studies have demonstrated that for every hour delay in the administration of appropriate antibiotic therapy there is an associated 7% rise in mortality. A large international collaboration was established to educate people about sepsis and to improve patient outcomes with sepsis, entitled the "Surviving Sepsis Campaign". The Campaign has published an evidence-based review of management strategies for severe sepsis,[5] with the aim to publish a complete set of guidelines in subsequent years.

Early goal directed therapy

Early goal directed therapy (EGDT), developed at Henry Ford Hospital by Emanuel Rivers, MD, is a systematic approach to resuscitation that has been validated in the treatment of severe sepsis and septic shock. It is meant to be started in the Emergency Department. The theory is that a step-wise approach should be used, having the patient meet physiologic goals, to optimize cardiac preload, afterload, and contractility, thus optimizing oxygen delivery to the tissues.[14] A recent meta-analysis showed that EGDT provides a benefit on mortality in patients with sepsis.[15] As of December 2008 some controversy around its uses remained, and a number of trials were in progress in an attempt to resolve this.[16]

In EGDT, fluids are administered until the central venous pressure (CVP), as measured by a central venous catheter, reaches 8–12 cm of water (or 10–15 cm of water in mechanically ventilated patients). Rapid administration of several liters of isotonic crystalloid solution is usually required to achieve this. If the mean arterial pressure is less than 65 mmHg or the systolic blood pressure is less than 90 mmHg, vasopressors or vasodilators are given as needed to reach the goal. Once these goals are met, the mixed venous oxygen saturation (SvO2), i.e., the oxygen saturation of venous blood as it returns to the heart as measured at the vena cava, is optimized. If the SvO2 is less than 70%, blood is given to reach a hemoglobin of 10 g/dl and then inotropes are added until the SvO2 is optimized. Elective intubation may be performed to reduce oxygen demand if the SvO2 remains low despite optimization of hemodynamics. Urine output is also monitored, with a minimum goal of 0.5 ml/kg/h. In the original trial, mortality was cut from 46.5% in the control group to 30.5% in the intervention group.[14] An appropriate decrease in serum lactate however may be equivalent to SvO2 and easier to obtain.[17] The Surviving Sepsis Campaign guidelines recommend EGDT for the initial resuscitation of the septic patient with a level B strength of evidence (single randomized control trial).[5]

Vasopressors

While a number of vasopressors can be used for septic shock norepinephrine appears superior to dopamine.[18]

Steroids

The use of steroids in sepsis is controversial.[6] During critical illness, a state of adrenal insufficiency and tissue resistance to corticosteroids may occur. This has been termed critical illness–related corticosteroid insufficiency.[19] Treatment with corticosteroids might be most beneficial in those with septic shock and early severe acute respiratory distress syndrome (ARDS), whereas its role in others such as those with pancreatitis or severe pneumonia is unclear.[19] However, the exact way of determining corticosteroid insufficiency remains problematic. It should be suspected in those poorly responding to resuscitation with fluids and vasopressors. ACTH stimulation testing is not recommended to confirm the diagnosis.[19] The method of cessation of glucocorticoid drugs is variable, and it is unclear whether they should be weaned or simply stopped abruptly.

Activated protein C

Recombinant activated protein C (drotrecogin alpha) in a 2011 Cochrane review was found not to decrease mortality, but to only increase adverse events, and thus was not recommended for use.[20] Other reviews, however, comment that it may be effective in those with very severe disease.[21] Nonetheless, it was removed from sale in October 2011.[8]

Neonates

Main article: Neonatal sepsis

Note that in neonates, sepsis is difficult to diagnose clinically. They may be relatively asymptomatic until hemodynamic and respiratory collapse is imminent. If there is even a remote suspicion of sepsis, they are frequently treated with antibiotics empirically until cultures are sufficiently proven to be negative.

Prognosis

Prognosis can be estimated with the Mortality in Emergency Department Sepsis (MEDS) score.[22] Approximately 20–35% of patients with severe sepsis and 40–60% of patients with septic shock die within 30 days. Others die within the ensuing 6 months. Late deaths often result from poorly controlled infection, immunosuppression, complications of intensive care, failure of multiple organs, or the patient's underlying disease.

Prognostic stratification systems such as APACHE II indicate that factoring in the patient's age, underlying condition, and various physiologic variables can yield estimates of the risk of dying of severe sepsis. Of the individual covariates, the severity of underlying disease most strongly influences the risk of death. Septic shock is also a strong predictor of short- and long-term mortality. Case-fatality rates are similar for culture-positive and culture-negative severe sepsis.

Some patients may experience severe long-term cognitive decline following an episode of severe sepsis, but the absence of baseline neuropsychological data in most sepsis patients makes the incidence of this difficult to quantify or to study.[23] A preliminary study of nine patients with septic shock showed abnormalities in seven patients by MRI.[24]

Epidemiology

In the United States sepsis is the second-leading cause of death in non-coronary Intensive Care Unit (ICU) patients, and the tenth-most-common cause of death overall according to data from the Centers for Disease Control and Prevention (the first being heart disease).[25] Sepsis is common and also more dangerous in elderly, immunocompromised, and critically ill patients.[26] It occurs in 1–2% of all hospitalizations and accounts for as much as 25% of ICU bed utilization. It is a major cause of death in intensive-care units worldwide, with mortality rates that range from 20% for sepsis, through 40% for severe sepsis, to over 60% for septic shock.

History

Severe systemic toxicity has been recognised since before the dawn of history but it was only in the 19th century that a specific term - sepsis - was coined for this condition. By the end of the 19th century, it was widely believed that microbes produced substances that could injure the mammalian host and that soluble toxins released during infection caused the fever and shock that were commonplace during severe infections. Pfeiffer coined the term endotoxin at the beginning of the 20th century to denote the pyrogenic principle associated with Vibrio cholerae. It was soon realised that endotoxins were expressed by most and perhaps all Gram negative organisms. The lipopolysaccharide character of enteric endotoxins was elucidated in the 1944 by Shear.[27] The molecular character of this material was determined by Luderitz et al in 1973.[28]

It was discovered in 1965 that a strain of C3H/HeJ mice were immune to the endotoxin induced shock.[29] The genetic locus for this effect was dubbed Lps. These mice were also found to be hypersusceptible to infection by Gram negative bacteria.[30] These observations were finally linked in 1998 by the discovery of the Toll-like receptor gene 4 (TLR 4).[31] Genetic mapping work, performed over a period of 5 years, showed that TLR4 was the sole candidate locus within the Lps critical region strongly implying that a mutation within TLR4 must account for the lipopolysaccharide resistance phenotype. The defect in the TLR4 gene that led to the endotoxin resistant phenotype was discovered to be due to a mutation in the cytoplasmic domain.[31]

It had previously been shown that cells of hematopoietic origin are required for the lethal effect of lipopolysaccharide.[32] Endotoxin sensitive mice may be rendered resistant to endotoxin if their bone marrow is ablated with radiation and it is then reconstituted with hematopoietic precursors derived from endotoxin resistant mice. Conversely, lipopolysaccharide sensitivity may be restored to resistant mice if they are colonized by hematopoietic precursors from endotoxin sensitive animals. These experiments showed that endotoxin was interacting with receptors on cells derived from the hematopoietic system to produce its effects.

In 1990 it was shown that CD14 acts to concentrate plasma lipopolysaccharide and that this effect evokes a strong response by mononuclear phagocytic cells.[33] Because CD14 lacks a cytoplasmic domain it was clear that at least one other protein was required for the endotoxin response. The Lps locus was considered to be the most likely candidate and so it proved.

Although it now known that endotoxin binds to CD14 and that CD14 then interacts with TLR4, the molecular details concerning precisely how this contributes to the generation of the septic syndrome are currently the subject of active research.

It was shown in 1999 that mutations in TLR 2 could significantly reduce the systemic response to Gram positive infections.[34] Although less likely than Gram negative organisms to cause septic shock, infection with Gram positive organisms remains a problem in intensive care and in neonates. Like TLR 4 much work is currently being done to elucidate the mechanism of the response to these organisms.


Society and culture

In 2012 a paper was published raising concerns regarding the use of hydroxyethyl starch in sepsis.[35] The pharmaceutical company, Fresenius Kabi, that makes the product is threatening to bring legal action against the author, Anders Perner, as they disagree with the results.[36] The academic community has raised concerns regarding this sort of behavior by a corporation.[36]

Research

PD-1

PD-1 was found to be up-regulated on monocytes/macrophages during sepsis in human and mice. This up-regulation was related to the up-regulation of IL-10 levels in the blood.[37] Interestingly, Said et al. showed that activated monocytes, which is the case in sepsis, express high levels of PD-1 and that triggering monocytes-expressed PD-1 by its ligand PD-L1 induces IL-10 production which inhibits CD4 T-cell function.[38]

Inflammatory signal blocker

A study reported in the journal Science showed that SphK1 is highly elevated in inflammatory cells from patients with sepsis and inhibition of the molecular pathway reduced the proinflammatory response triggered by bacterial products in the human cells. Moreover, the study also showed the mortality rate of mice with experimental sepsis was reduced when treated with a SphK1 blocker.[39] Similarly, inhibition of the p38 MAPK signaling transduction pathway may help to block enhanced procoagulatory activities during septicemia.[40]

Nitric oxide

Medical research is focused on combating nitric oxide. Attempts to inhibit its production paradoxically led to a worsening of the organ damage and in an increased lethality, both in animal models and in a clinical trial in sepsis patients. In a study published in the Journal of Experimental Medicine, nitrite treatment, in sharp contrast with the worsening effect of inhibiting NO-synthesis, significantly attenuates hypothermia, mitochondrial damage, oxidative stress and dysfunction, tissue infarction, and mortality in mice.[41]

References

  1. ^ a b Levy, Mitchell M.; Fink, Mitchell P.; Marshall, John C.; Abraham, Edward; Angus, Derek; Cook, Deborah; Cohen, Jonathan; Opal, Steven M.; Vincent, Jean-Louis (2003). "2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference". Critical Care Medicine. 31 (4): 1250–6. doi:10.1097/01.CCM.0000050454.01978.3B. PMID 12682500.
  2. ^ a b c d Bone, R.; Balk, R.; Cerra, F.; Dellinger, R.; Fein, A.; Knaus, W.; Schein, R.; Sibbald, W. (1992). "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine". Chest. 101 (6): 1644–55. doi:10.1378/chest.101.6.1644. PMID 1303622.
  3. ^ http://dictionary.reference.com/search?q=Septicemia
  4. ^ Template:EMedicineDictionary
  5. ^ a b c Dellinger, R Phillip; Levy, Mitchell M.; Carlet, Jean M.; Bion, Julian; Parker, Margaret M.; Jaeschke, Roman; Reinhart, Konrad; Angus, Derek C.; Brun-Buisson, Christian (2008). "Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008". Critical Care Medicine. 36 (1): 296–327. doi:10.1097/01.CCM.0000298158.12101.41. PMID 18158437.
  6. ^ a b Patel, GP (2012 Jan 15). "Systemic steroids in severe sepsis and septic shock". American Journal of Respiratory and Critical Care Medicine. 185 (2): 133–9. PMID 21680949. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  7. ^ Martí-Carvajal, AJ (2011-04-13). "Human recombinant activated protein C for severe sepsis". Cochrane database of systematic reviews (Online) (4): CD004388. doi:10.1002/14651858.CD004388.pub4. PMID 21491390. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  8. ^ a b https://investor.lilly.com/releasedetail2.cfm?ReleaseID=617602
  9. ^ Bone RC, Balk RA, et al. (The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine) (June 1992). "Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis". Chest. 101 (6): 1644–55. doi:10.1378/chest.101.6.1644. PMID 1303622.
  10. ^ Abraham, Edward; Singer, Mervyn (2007). "Mechanisms of sepsis-induced organ dysfunction". Critical Care Medicine. 35 (10): 2408–16. doi:10.1097/01.CCM.0000282072.56245.91. PMID 17948334.
  11. ^ Goldstein B, Giroir B, Randolph A (2005). "International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics". Pediatr Crit Care Med. 6 (1): 2–8. doi:10.1097/01.PCC.0000149131.72248.E6. PMID 15636651.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  12. ^ Lockhart, P. B.; Brennan, M. T.; Sasser, H. C.; Fox, P. C.; Paster, B. J.; Bahrani-Mougeot, F. K. (2008). "Bacteremia Associated with Tooth Brushing and Dental Extraction". Circulation. 117 (24): 3118–25. doi:10.1161/CIRCULATIONAHA.107.758524. PMC 2746717. PMID 18541739.
  13. ^ Wilson, W.; Taubert, K. A.; Gewitz, M.; Lockhart, P. B.; Baddour, L. M.; Levison, M.; Bolger, A.; Cabell, C. H.; Takahashi, M. (2007). "Prevention of Infective Endocarditis: Guidelines from the American Heart Association: A Guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group". Circulation. 116 (15): 1736–54. doi:10.1161/CIRCULATIONAHA.106.183095. PMID 17446442.
  14. ^ a b Rivers, Emanuel; Nguyen, Bryant; Havstad, Suzanne; Ressler, Julie; Muzzin, Alexandria; Knoblich, Bernhard; Peterson, Edward; Tomlanovich, Michael; Early Goal-Directed Therapy Collaborative Group (2001). "Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock". New England Journal of Medicine. 345 (19): 1368–77. doi:10.1056/NEJMoa010307. PMID 11794169.
  15. ^ Jones, Alan E.; Brown, Michael D.; Trzeciak, Stephen; Shapiro, Nathan I.; Garrett, John S.; Heffner, Alan C.; Kline, Jeffrey A.; Emergency Medicine Shock Research Network investigators (2008). "The effect of a quantitative resuscitation strategy on mortality in patients with sepsis: A meta-analysis". Critical Care Medicine. 36 (10): 2734–9. doi:10.1097/CCM.0b013e318186f839. PMC 2737059. PMID 18766093.
  16. ^ McKenna, Maryn (2008). "Controversy Swirls Around Early Goal-Directed Therapy in Sepsis: Pioneer Defends Ground-Breaking Approach to Deadly Disease". Annals of Emergency Medicine. 52 (6): 651–4. doi:10.1016/j.annemergmed.2008.10.013. PMID 19048659.
  17. ^ Jones, AE (2010 Feb 24). "Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial". JAMA: the Journal of the American Medical Association. 303 (8): 739–46. doi:10.1001/jama.2010.158. PMC 2918907. PMID 20179283. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  18. ^ De Backer, D (2012 Mar). "Dopamine versus norepinephrine in the treatment of septic shock: A meta-analysis*". Critical Care Medicine. 40 (3): 725–30. doi:10.1097/CCM.0b013e31823778ee. PMID 22036860. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  19. ^ a b c Marik, Paul E.; Pastores, Stephen M.; Annane, Djillali; Meduri, G Umberto; Sprung, Charles L.; Arlt, Wiebke; Keh, Didier; Briegel, Josef; Beishuizen, Albertus (2008). "Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: Consensus statements from an international task force by the American College of Critical Care Medicine". Critical Care Medicine. 36 (6): 1937–49. doi:10.1097/CCM.0b013e31817603ba. PMID 18496365.
  20. ^ Martí-Carvajal, Arturo J; Solà, Ivan; Lathyris, Dimitrios; Cardona, Andrés Felipe (2011). Martí-Carvajal, Arturo J (ed.). "Cochrane Database of Systematic Reviews". Cochrane Database Syst Rev (4): CD004388. doi:10.1002/14651858.CD004388.pub4. PMID 21491390. {{cite journal}}: |chapter= ignored (help)
  21. ^ Sandrock, Christian; Albertson, Timothy (2010). "Controversies in the Treatment of Sepsis". Seminars in Respiratory and Critical Care Medicine. 31 (1): 66–78. doi:10.1055/s-0029-1246290. PMID 20101549.
  22. ^ Shapiro, Nathan I.; Wolfe, Richard E.; Moore, Richard B.; Smith, Eric; Burdick, Elizabeth; Bates, David W. (2003). "Mortality in Emergency Department Sepsis (MEDS) score: A prospectively derived and validated clinical prediction rule". Critical Care Medicine. 31 (3): 670–5. doi:10.1097/01.CCM.0000054867.01688.D1. PMID 12626967.
  23. ^ Jackson, James C.; Hopkins, Ramona O.; Miller, Russell R.; Gordon, Sharon M.; Wheeler, Arthur P.; Ely, E Wesley (2009). "Acute Respiratory Distress Syndrome, Sepsis, and Cognitive Decline: A Review and Case Study". Southern Medical Journal. 102 (11): 1150–1157. doi:10.1097/SMJ.0b013e3181b6a592. PMID 19864995.
  24. ^ Sharshar, Tarek; Carlier, Robert; Bernard, Francis; Guidoux, CéLine; Brouland, Jean-Philippe; Nardi, Olivier; Grandmaison, Geoffroy Lorin; Aboab, Jérôme; Gray, FrançOise (2007). "Brain lesions in septic shock: a magnetic resonance imaging study". Intensive Care Medicine. 33 (5): 798–806. doi:10.1007/s00134-007-0598-y. PMID 17377766.
  25. ^ Martin, Greg S.; Mannino, David M.; Eaton, Stephanie; Moss, Marc (2003). "The Epidemiology of Sepsis in the United States from 1979 through 2000". New England Journal of Medicine. 348 (16): 1546–54. doi:10.1056/NEJMoa022139. PMID 12700374.
  26. ^ Cohen, Elizabeth (January 29, 2009). "Sepsis can strike, kill shockingly fast". CNN.
  27. ^ Shear MJ (1944) Chemical treatment of tumors, IX: reactions of mice with primary subcutaneous tumors to injection of a hemorrhage-producing bacterial polysaccharide. J Natl Canc Inst 4: 461-476
  28. ^ Luderitz O; Galanos C; Lehmann V (1973). "Lipid A: chemical structure and biologic activity". J Infect Dis. 128: 29. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  29. ^ Heppner G, Weiss DW (1965). "High susceptibility of strain A mice to endotoxin and endotoxin-red blood cell mixtures". J Bacteriol. 90 (3): 696–703. PMC 315712. PMID 16562068.
  30. ^ O'Brien AD; Rosenstreich DL; Scher I; et al. (1980). "Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene". J Immunol. 124 (1): 20–24. PMID 6985638. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  31. ^ a b Poltorak A, Smirnova I, He XL et al (1998) Genetic and physical mapping of the Lps locus-identification of the toll-4 receptor as a candidate gene in the critical region. Blood Cells Mol Dis 24: 340-355 Cite error: The named reference "Poltorak1998" was defined multiple times with different content (see the help page).
  32. ^ Michalek SM; Moore RN; McGhee JR; et al. (1980). "The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxin". J Infect Dis. 141 (1): 55–63. doi:10.1093/infdis/141.1.55. PMID 6154108. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  33. ^ Wright SD; Ramos RA; Tobias PS; et al. (1990). "CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein". Science. 249 (4975): 1431–1433. doi:10.1126/science.1698311. PMID 1698311. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  34. ^ Takeuchi O; Hoshino K; Kawai T; et al. (1999). "Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components". Immunity. 11 (4): 443–451. doi:10.1016/S1074-7613(00)80119-3. PMID 10549626. {{cite journal}}: Unknown parameter |author-separator= ignored (help)
  35. ^ Perner, A (2012 Jul 12). "Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis". The New England Journal of Medicine. 367 (2): 124–34. PMID 22738085. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  36. ^ a b Wojcik, Jeppe (July 24,2012). "Pharma giant threatens Danish scientist". ScienceNordic. Retrieved 13 August 2012. {{cite news}}: Check date values in: |date= (help)
  37. ^ Huang, X.; Venet, F.; Wang, Y. L.; Lepape, A.; Yuan, Z.; Chen, Y.; Swan, R.; Kherouf, H.; Monneret, G. (2009). "PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis". Proceedings of the National Academy of Sciences. 106 (15): 6303–8. doi:10.1073/pnas.0809422106.
  38. ^ Said, Elias A; Dupuy, Franck P; Trautmann, Lydie; Zhang, Yuwei; Shi, Yu; El-Far, Mohamed; Hill, Brenna J; Noto, Alessandra; Ancuta, Petronela (2010). "Programmed death-1–induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection". Nature Medicine. 16 (4): 452–9. doi:10.1038/nm.2106. PMID 20208540.
  39. ^ . doi:10.1126/science.1188635. PMID 20522778. {{cite journal}}: Cite journal requires |journal= (help); Missing or empty |title= (help); Unknown parameter |laysummary= ignored (help)
  40. ^ Danckwardt, Sven; Gantzert, Anne-Susan; Macher-Goeppinger, Stephan; Probst, Hans Christian; Gentzel, Marc; Wilm, Matthias; Gröne, Hermann-Josef; Schirmacher, Peter; Hentze, Matthias W. (2011). "p38 MAPK Controls Prothrombin Expression by Regulated RNA 3′ End Processing". Molecular Cell. 41 (3): 298–310. doi:10.1016/j.molcel.2010.12.032. PMID 21292162.
  41. ^ http://www.physorg.com/news180096790.html

Template:Link FA

Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Sepsis&oldid=520883893"